Indian Equities Slip on Thursday as US Tariff Impact Weighs

MT Newswires Live04-03

Indian markets closed lower on Thursday as investors reacted to US President Donald Trump's announcement of a 26% tariff on Indian exports.

However, the exclusion of pharmaceutical products from the tariff list resulted in a rally in domestic pharma stocks, given the sector's significant exposure to the US market.

The BSE Sensex declined 322.08 points, or 0.4%, to 76,295.36, while the NSE Nifty 50 dropped 82.25 points, or also 0.4%, to 23,250.10.

Tata Consultancy Services (NSE:TCS, BOM:532540) led the laggards, falling 4%, followed by HCLTech (NSE:HCLTECH, BOM:532281) and Tech Mahindra (NSE:TECHM, BOM:532755).

Power Grid Corp. of India (NSE:POWERGRID, BOM:532898), Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715), and Cipla (NSE:CIPLA, BOM:500087) were the top gainers.

In corporate updates, Bajaj Finance (NSE:BAJFINANCE, BOM:500034) raised 59.9 billion rupees Indian via the allotment of non-convertible debentures in two tranches, according to a Thursday filing. The securities will be listed on the BSE Wholesale Debt Market Segment.

Meanwhile, Gland Pharma (NSE:GLAND, BOM:543245) received US FDA approval for Acetaminophen injection bags, a bioequivalent and therapeutically equivalent alternative to B. Braun Medical's reference drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment